What is Zyvox?
Zyvox is an antimicrobial drug of the oxazolidinone class, which is active against anaerobic microorganisms, a wide range of aerobic gram-positive bacteria, and some gram-negative bacteria.
Indications for use
Zyvox antibiotic is used for the treatment of infectious and inflammatory diseases when it is suspected or is known for certain that they were caused by aerobic and anaerobic gram-positive microorganisms sensitive to linezolid (including infections accompanied by bacteremia):
- Community-acquired pneumonia: the causative agent is Streptococcus pneumoniae (including its multiresistant strains, including those associated with bacteremia); pathogen – Staphylococcus aureus (exclusively methicillin-sensitive strains);
- Nosocomial (hospital) pneumonia: pathogen – Staphylococcus aureus (including methicillin-resistant and methicillin-sensitive strains); pathogen – Streptococcus pneumoniae (including multiresistant strains);
- Complicated infections of soft tissues and skin, including infections with diabetic foot syndrome (SDS), without signs of osteomyelitis: pathogens – Staphylococcus aureus (including methicillin-resistant and methicillin-sensitive strains), Streptococcus agalactiae and Streptococcus pyogenes;
- Uncomplicated infections of soft tissues and skin: pathogens – Staphylococcus aureus (exclusively strains sensitive to methicillin) or Streptococcus pyogenes;
- Vancomycin-resistant infections: the causative agent is Enterococcus faecium, including infections accompanied by bacteremia.
All forms of Zyvox release are contraindicated in case of hypersensitivity to the components of the drug.
Absolute contraindications for oral administration of Zyvox (tablets, granules):
- Concomitant use of monoamine oxidase A or B inhibitors (isocarboxazide, phenelzine), as well as a two-week period after stopping their use;
- The inability to control blood pressure during the treatment of patients with pheochromocytoma, uncontrolled arterial hypertension, thyrotoxicosis, as well as patients receiving adrenomimetics (phenylpropanolamine, pseudoephedrine, epinephrine, dobutamine) and / or dopaminomimetics (levodopa, amantadine, dopamine);
- Inability to monitor patients at risk for serotonin syndrome;
- Carcinoid syndrome and / or administration of serotonin reuptake inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists (triptans), meperidine or buspirone;
- Children’s age up to 12 years (for tablets, due to the impossibility of adequate dose selection).
Relative contraindications (increased risk of side effects):
- Severe renal failure;
- Liver failure;
- Systemic infections that pose a risk to life (using venous catheters in intensive care units);
- Lactation period.
Instruction for use
Depending on the causative agent of infection, localization and severity of the course of the disease, as well as on clinical effectiveness, the duration of the course of therapy and the dosage regimen are determined.
Zyvox tablets are taken orally, regardless of food intake. Recommended dosing regimen for the treatment of infections (including those associated with bacteremia):
- Community-acquired pneumonia, hospital pneumonia – 600 mg every 12 hours for 11 / 2-2 weeks;
- Soft tissue and skin infections – from 400 to 600 mg (depending on the severity of the disease) every 12 hours for 11 / 2-2 weeks;
- Enterococcal infections – 600 mg every 12 hours for 2-4 weeks.
For children from 5 years and older (from 12 years – for tablets) Zyvox is recommended at a dose of 10 mg / kg body weight per day, divided into 2 doses.
For children and adults, the maximum dose should not exceed 600 mg 2 times a day.
Undesirable effects associated with taking Zyvox oral forms of mild or moderate severity are usually observed. Most often, headache, nausea, and diarrhea were noted.